| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9969fd051f07753eeb09aebfdf8efd74 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 |
| filingDate |
2020-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8fea0b2833bceadd3671650c5d42c68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46a05762690716c5384ad7030f3e8f77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec702aa56b2252cdfe5501f5cc2f90df |
| publicationDate |
2021-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021045804-A1 |
| titleOfInvention |
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| abstract |
A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflurmilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021155173-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023177416-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11129818-B2 |
| priorityDate |
2018-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |